FDA grants Cary's Chiesi new designation

With construction of a new headquarters overlooking Symphony Lake currently underway, expanding Cary-based pharmaceutical company Chiesi USA has received a nod from the U.S. Food and Drug Administration for a new stem cell therapy. Chiesi USA – along with Italian biotech Holostem Terapie Avanzate – have been granted orphan drug designation from the FDA for an investigational therapy for a type of stem cell deficiency. The therapy – called GPLSCD01 – is being developed to treat Limbal Stem…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news